Aptiom (eslicarbazepine acetate) Coverage Criteria
Customize your policy alerts
Sign up for Oscar Health Policy PG174 alerts
Get alerted when Policy PG174 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity review for Aptiom (eslicarbazepine acetate) in members aged 4 years and older with focal-onset seizures. It requires specialist involvement, use or failure of alternative antiepileptic drugs, appropriate dosing, and compliance with the quantity limit.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.